CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Curcumin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01740323
NCT01740323Phase 2Completed
CompareCT.gov

Meriva for Treatment-induced Inflammation and Fatigue in Women With Breast Cancer

Andrew H Miller·interventional·Posted Dec 4, 2012·Updated Sep 18, 2019

In Brief

A Phase 2 clinical trial evaluating Placebo and Curcumin for Breast Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The main purpose of the investigation is to determine if curcumin reduces NF-kB DNA binding and ultimately its downstream mediator IL-6 in patients receiving XRT for their breast cancer after having completed chemotherapy. Patients who have received prior chemotherapy will be eligible, because we have found that this enriched population is at particular risk for exhibiting increased NF-kB DNA binding and IL-6 following XRT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 4, 2012
Enrollment StartMay 1, 2015
Primary CompletionJul 27, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.6 years ago

Interventions

Placebodrug

daily placebo for 6 weeks

Curcumindrug

500 mg BID